title: Identification of two H3-histamine receptor subtypes.
abstract: The H3-histamine receptor provides feedback inhibition of histamine synthesis and release as well as inhibition of other neurotransmitter release. We have characterized this receptor by radioligand binding studies with the H3 agonist N alpha-[3H]methylhistamine ([3H]NAMHA). The results of [3H]NAMHA saturation binding and NAMHA inhibition of [3H]NAMHA binding were consistent with an apparently single class of receptors (KD = 0.37 nM, Bmax = 73 fmol/mg of protein) and competition assays with other agonists and the antagonists impromidine and dimaprit disclosed only a single class of sites. In contrast, inhibition of [3H]NAMHA binding by the specific high affinity H3 antagonist thioperamide revealed two classes of sites (KiA = 5 nM, BmaxA = 30 fmol/mg of protein; KiB = 68 nM, BmaxB = 48 fmol/mg of protein). Burimamide, another antagonist that, like thioperamide, contains a thiourea group, likewise discriminated between two classes of sites. In addition to differences between some antagonist potencies for the two receptors, there is a differential guanine nucleotide sensitivity of the two. The affinity of the H3A receptor for [3H] NAMHA was reduced less than 2-fold, whereas [3H]NAMHA binding to the H3B receptor was undetectable in the presence of guanosine 5'-O-(3-thiotriphosphate). The distinction between H3A and H3B receptor subtypes, the former a high affinity and the latter a low affinity thioperamide site, draws support from published in vitro data.
authors.affiliation: Department of Allergy and Immunology, Schering-Plough Research, Bloomfield, New Jersey 07003.
authors.forename: R E
authors.initials: RE
authors.lastname: West
authors.forename: A
authors.initials: A
authors.lastname: Zweig
authors.forename: N Y
authors.initials: NY
authors.lastname: Shih
authors.forename: M I
authors.initials: MI
authors.lastname: Siegel
authors.forename: R W
authors.initials: RW
authors.lastname: Egan
authors.forename: M A
authors.initials: MA
authors.lastname: Clark
mesh_terms: D000818:Animals; D001665:Binding Sites / Q000187:drug effects; D001667:Binding, Competitive; D001923:Brain Chemistry; D002049:Burimamide / Q000494:pharmacology; D017259:Dimaprit; D006146:Guanidines / Q000494:pharmacology; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000494:pharmacology; D006632:Histamine / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D017446:Impromidine; D008297:Male; D008761:Methylhistamines / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology*; D011869:Radioligand Assay; D051381:Rats; D011919:Rats, Inbred Strains; D011968:Receptors, Histamine / Q000032:analysis / Q000145:classification* / Q000187:drug effects; D018100:Receptors, Histamine H3; D013890:Thiourea / Q000494:pharmacology; D014316:Tritium
chemical_list: D006146:Guanidines; D007093:Imidazoles; D008761:Methylhistamines; D010880:Piperidines; D011968:Receptors, Histamine; D018100:Receptors, Histamine H3; D014316:Tritium; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D006632:Histamine; D017446:Impromidine; D013890:Thiourea; C052075:thioperamide; D002049:Burimamide; C048140:N-methylhistamine; D017259:Dimaprit